Home Newsfeeds Keybanc Maintains Overweight on Arista Networks, Lowers Price Target to $161

Keybanc Maintains Overweight on Arista Networks, Lowers Price Target to $161

Keybanc analyst Thomas Blakey maintains Arista Networks (NYSE:ANET) with a Overweight and lowers the price target from $170 to $161.

byBenzinga Newsdesk

November 1, 2022

1 minute read

Keybanc analyst Thomas Blakey maintains Arista Networks (NYSE:ANET) with a Overweight and lowers the price target from $170 to $161.

News
Tech

Google’s Head-Scratcher: Will Your Hidden Gems Disappear Or Persist? The Album Archive Puzzle

By Ananya Gairola

June 19, 5:30 AM

Google's impending shutdown of Album Archive has users questioning the destiny of their cherished photos and videos, leaving them to wonder whether these hidden gems will vanish or find sanctuary in alternative Google services.

AAPL

Why MillerKnoll Stock Surged After Hours

By Ryan Gustafson

September 26, 4:44 PM

MillerKnoll, Inc. (NASDAQ: MLKN) shares are trading higher in Tuesday's after-hours session after the company reported first-quarter earnings.

MLKN

Acushnet Holdings Q4 Sales $447.40M Beat $427.70M Estimate

By Benzinga Newsdesk

March 1, 7:47 AM

Acushnet Holdings (NYSE:GOLF) reported quarterly sales of $447.40 million which beat the analyst consensus estimate of $427.70 million by 4.61 percent. This is a 6.38 percent increase over sales of $420.57 million the

GOLF

Regulus Therapeutics Announces First Patient Dosed In Second Cohort Of Phase 1b Multiple-Ascending Dose Clinical Trial Of RGLS8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease

By Happy Mohamed

June 27, 8:03 AM

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced

RGLS

Keybanc Maintains Overweight on Arista Networks, Lowers Price Target to $161

Related Posts

Google’s Head-Scratcher: Will Your Hidden Gems Disappear Or Persist? The Album Archive Puzzle

Why MillerKnoll Stock Surged After Hours

Acushnet Holdings Q4 Sales $447.40M Beat $427.70M Estimate

Regulus Therapeutics Announces First Patient Dosed In Second Cohort Of Phase 1b Multiple-Ascending Dose Clinical Trial Of RGLS8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease